{"denoms":[{"counts":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"50"}],"units":"Participants"}],"groups":[{"description":"Fludarabine 30 mg/m\\^2 intravenous (IV) daily over 30 minutes for 4 Days (Beginning Day -4).\n\nMelphalan 140 mg/m\\^2 IV over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m\\^2 IV infused starting on day -5.","id":"BG000","title":"Fludarabine + Melphalan + Stem Cell Infusion"},{"description":"Fludarabine 30 mg/m\\^2 intravenous daily over 30 minutes for 4 Days (Beginning Day -4).\n\nLower-Dose Melphalan 100 mg/m\\^2 intravenous over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m\\^2 intravenous infused starting on day -5.","id":"BG001","title":"Fludarabine + Lower-Dose Melphalan + Stem Cell Infusion"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"32","upperLimit":"64","value":"52"},{"groupId":"BG001","lowerLimit":"36","upperLimit":"64","value":"53"},{"groupId":"BG002","lowerLimit":"32","upperLimit":"64","value":"53"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"20"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"30"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"50"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}